top of page
ChatGPT Image 15 sept 2026, 13_11_47.png

Turning molecular insights into better decisions for more patients

INVEST IN A CLEARER TOMORROW

Altum Sequencing is raising €5M
to scale globally

We combine liquid biopsy, ultra-sensitive NGS and AI to monitor cancer treatment, detect molecular relapse earlier and identify emerging resistance.

25+

Customers

6.000+

Samples analyzed

3

Key markets:

Pharma | Hospitals
Clinical research

€5M

Round size

01_investment_opportunity.png
Investment opportunity

Why now, why Altum and how we will use the €5M.

Close
02_our_technology.png
Our technology

Liquid biopsy, ultra-sensitive NGS and AI for personalized cancer monitoring.

Close
03_traction.png
Traction

From a leading hospital to 25+customers and 6.000+ samples.

Close
04_altum_atlas_ai.png
Altum ATLAS
& AI

Longitudinaldata, AI-powered noise reduction and lower analysis costs to scale.

Close
05_our_team.png
Our team

A multidisplinary team with deep scientific, clinical and business expertise.

Close
ChatGPT Image 15 sept 2026, 14_38_19.png
INVESTMENT OPPORTUNITY

A €5M opportunity to scale cancer monitoring globally

Join us in building the next global leader in personalized cancer monitoring through liquid biopsy, ultra-sensitive NGS and AI.
01_investment_opportunity.png

Large Market

02_our_technology.png

Differentiated
Technology

03_traction.png

Strong Traction

04_altum_atlas_ai.png

Experienced Team

To accelerate regulatory development, scale Altum ATLAS and expand internationally.

Round size

€5M

Why now?

Growing demand for molecular monitoring.

Expanding use in clinical trials and routine care.

Clear regulatory and reimbursement pathway.

Attractive M&A potential.

More insight today.
A better tomorrow

Invest in a brighter tomorrow

ChatGPT Image 15 sept 2026, 14_44_07.png
Ultra-sensitive NGS, propietary panels and AI-powered analysis to monitor cancer over time.

Liquid biopsy meet precision and scale

OUR TECHNOLOGY
One patient. Multiple decisions. One longitudinal platform.
ChatGPT Image 10 sept 2026, 14_22_28.png
Diagnosis
Treatment
Response
monitoring
Remission / MRD
Tumor
Evolution
Treatment
resistance
Relapse

Altum Dx
Panels

Altum TRACKseq
Disease monitoring / MRD

Altum EVOseq
Resistance / clonal evolution

Altum
TRACKseq

Altum DUALseq
Disease + therapy monitoring

Altum ATLAS
Longitudinal integration + clinical / research intelligence

How it works
Pruebas web Ricardo.png
Altum TRACKseq.png

MRD Monitoring

Altum EVOseq.png

Clonal evolution
& resistence

Altum DUAL.png

MRD + cell therapy
monitoring

Altum Dx Panels.png

Baseline genomic
profiling

Built for a Clinical and commercial scale

High sensitivity

Automated workflows

Cost-effective scalability

ChatGPT Image 15 sept 2026, 14_51_22.png
TRACTION

From a leading hospital to global impact

Real data. Real collaborations. Real progress.

Commercial Traction Across Europe, US & Asia

Pruebas web Ricardo (1).png

Evidence that matters

5,7 years

maximum lead
time before clinical recurrence

(Breast cancer patients)

99%

Specificity (B-cell lymphoma patients)

(DLBCL, FL)

97%

relapses detected at end of treatment

(Follicular lymphoma patients)

"Altum Sequencing’s approach to longitudinal
molecular monitoring has the potential to change how
we manage cancer treatment."
Dr. Joaquín Martínez

Chairman and Co-Founder
Head of Hematology at Hospital 12 de Octubre

Evidence-driven traction,
built to scale

25+ customers

6,000+ samples analyzed

23 cancer types tested

ChatGPT Image 15 sept 2026, 14_48_46.png
ALTUM ATLAS & AI

Turning complex
data into clinical
insight

A platform to integrate, analyze and visualize  longitudinal molecular data.
Powered by AI.
ChatGPT Image 16 sept 2026, 15_30_11.png

Longitudinal
patient view

02_ai_powered_noise_reduction.png

AI-powered
noise reduction

03_automated_analysis.png

Automated
analysis

04_actionable_insights(1).png

Actionable
insights

Integrate Multiple
data sources

circulating tumor dNA (nGS)

Imaging (PET)

Clinical data

Founder team.png
OUR TEAM

A multidisciplinary
team with a shared purpose

Science, clinical expertise and entrepreneurial experience to build a global leader in cancer monitoring
01_scientific_expertise.png

World-class
scientific founder

02_leadership_team.png

Experienced
leadership team

03_diverse_global_team.png

Diverse and
talented organization

1.png
3.png
4.png
2.png
5.png

Scientific excellence.
experienced leadership.

Built to execute and scale

bottom of page